Advanced glycation endproducts--role in pathology of diabetic complications.

By N. Ahmed. Diabetes Research and Clinical Practice, 2005

1,479 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Diabetic neuropathy: mechanisms to management. (2008, background): “4d. AGE Pathway Non-enzymatic reactions between reducing sugars or oxaldehydes and proteins/lipids result in advanced glycation endproducts (AGEs) (Ahmed, 2005; Toth, 2007).”
Oxidative Stress in Aging Human Skin (2015, background): “In addition to these problems there is evidence that the removal of AGEs poses a big problem for the cell.”
Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives (2022, background): “The deleterious effects of AGEs are underpinned by their ability to trigger the release of pro-inflammatory molecules, impair mitochondrial oxidative stress, activate AGEs/RAGE signaling cascade, and trigger transcription factors that upregulate the expression of genes which have potential roles in ”
Dietary factors and low-grade inflammation in relation to overweight and obesity (2011, neutral): “In fact, others have found low to undetectable AGE levels in unconcentrated normal or diet cola((466,544)).”
Advanced Glycation End Products and Diabetic Complications (2014, background): “AGEs are important causative factors for the pathogenesis of diabetes [29], cataracts [30], atherosclerosis [31], diabetic nephropathy [32], and neurodegenerative diseases, including Alzheimer’s disease [33].”